{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/fueling-early-stage-biotech-growth-adaptive-patient-inclusive-fih-trials-1#webpage",
"url": "https://www.fortrea.com/insights/fueling-early-stage-biotech-growth-adaptive-patient-inclusive-fih-trials-1",
"name": "Fueling early-stage biotech growth with adaptive, patient-inclusive FIH trials",
"description": "This Fortrea case study explores how adaptive, patient-inclusive first in human (FIH) trials supported early-stage biotech growth through more efficient early phase clinical development strategies. The study implemented a hybrid adaptive design that combined healthy volunteer and patient cohorts within a single protocol, enabling earlier evaluation of safety, tolerability, pharmacokinetics, and preliminary efficacy. By integrating adaptive methodologies with patient-inclusive approaches, the strategy improved operational flexibility, accelerated decision-making, and reduced development timelines for the biotech sponsor. The case study highlights how innovative FIH trial design, streamlined execution, and integrated clinical pharmacology expertise can support faster progression in early clinical development while maintaining patient safety and study quality."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Fueling early-stage biotech growth with adaptive, patient-inclusive FIH trials",
"item": "https://www.fortrea.com/insights/fueling-early-stage-biotech-growth-adaptive-patient-inclusive-fih-trials-1"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/fueling-early-stage-biotech-growth-adaptive-patient-inclusive-fih-trials-1#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/fueling-early-stage-biotech-growth-adaptive-patient-inclusive-fih-trials-1#webpage"
},
"headline": "Adaptive Patient-Inclusive FIH Trials for Early-Stage Biotech Growth | Fortrea Case Study",
"description": "This Fortrea case study explores how adaptive, patient-inclusive first in human (FIH) trials supported early-stage biotech growth through more efficient early phase clinical development strategies. The study implemented a hybrid adaptive design that combined healthy volunteer and patient cohorts within a single protocol, enabling earlier evaluation of safety, tolerability, pharmacokinetics, and preliminary efficacy. By integrating adaptive methodologies with patient-inclusive approaches, the strategy improved operational flexibility, accelerated decision-making, and reduced development timelines for the biotech sponsor. The case study highlights how innovative FIH trial design, streamlined execution, and integrated clinical pharmacology expertise can support faster progression in early clinical development while maintaining patient safety and study quality.",
"genre": "Case Study",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-11-26",
"dateModified": "2025-11-26",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-11/adaptive-patient-inclusive-fih-trials.pdf",
"encodingFormat": "application/pdf"
}
}
]
}